Interstitial lung disease is not a single condition with a neat four-stage ladder. It is an umbrella term covering more than 200 disorders that scar or inflame the tissue between the air sacs of the lungs, and no single staging system applies across all of them. When people search for “the four stages,” they are usually encountering either the Scadding classification for pulmonary sarcoidosis, which runs from Stage 0 through Stage IV, or a simplified description of how fibrotic lung disease generally worsens over time. Understanding which framework applies, and why the reality is messier than a tidy numbered list, matters for anyone trying to make sense of a diagnosis.
Why No Single Four-Stage System Exists
The family of interstitial lung diseases includes idiopathic pulmonary fibrosis (IPF), sarcoidosis, hypersensitivity pneumonitis, connective tissue disease-related ILD, and many others. Each has a different cause, a different typical course, and a different way of being classified. A staging system that works well for sarcoidosis, where lymph node swelling and lung scarring follow a somewhat predictable radiographic pattern, would make little sense for IPF, where the lungs scar progressively without that same lymph-node involvement. So clinicians use disease-specific tools rather than one universal ladder.
That said, two frameworks come up most often in clinical practice and patient conversations. The Scadding classification, developed for sarcoidosis, is the one with stages numbered 0 through IV. The ILD-GAP model, used more broadly across fibrotic lung diseases, assigns patients to one of three prognostic stages based on a mix of age, sex, and lung function. Neither of these is “the four stages of ILD” in the way cancer staging works, but together they give a useful picture of how clinicians think about disease severity.
The Scadding Classification for Sarcoidosis
Sarcoidosis is one of the most common ILDs, and its staging system is probably what most people encounter when they read about “stages of interstitial lung disease.” Developed by radiologist J.G. Scadding, it uses chest imaging to categorize the disease into five stages based on what the lungs and lymph nodes look like on X-ray or CT scan:
- Stage 0: No visible lung involvement on imaging.
- Stage I: Enlarged lymph nodes in the center of the chest (bilateral hilar lymphadenopathy) without lung tissue changes.
- Stage II: Enlarged lymph nodes plus interstitial lung disease visible on imaging.
- Stage III: Interstitial lung disease visible on imaging, but the lymph node enlargement has resolved.
- Stage IV: Permanent lung fibrosis, meaning irreversible scarring has replaced functional tissue.
These stages are assessed using both chest X-rays and CT scans, sometimes by independent observers to improve consistency.1CHEST. Clinical Profile and Staging of Pulmonary Sarcoidosis One important caveat: the Scadding stages do not always march forward in order. Many people with Stage I sarcoidosis experience spontaneous remission and never progress. Others jump from Stage II directly to Stage IV. The stage number reflects what the imaging looks like at a given moment, not necessarily a fixed position on a one-way escalator.
The ILD-GAP Staging System
For fibrotic ILDs beyond sarcoidosis, the more widely used prognostic tool is the ILD-GAP model. GAP stands for Gender, Age, and Physiology, and the system was designed to estimate mortality risk. It assigns points based on whether the patient is male or female, their age bracket, and two key lung function measurements: forced vital capacity (FVC, how much air you can blow out) and diffusing capacity for carbon monoxide (DLCO, how well oxygen crosses from the lungs into the blood). Those points are then totaled and sorted into three stages, not four.
The distinction between these stages is clinically meaningful. In one study of patients with ILD undergoing lung cancer surgery, the five-year survival rate for people in ILD-GAP Stage I was about 74%, compared with roughly 73% for Stage II and just 13% for Stage III.2Clinical Lung Cancer. Clinical Outcomes and Prognosis of Patients With Interstitial Lung Disease Undergoing Lung Cancer Surgery: A Propensity Score Matching Study That steep drop-off between Stage II and Stage III illustrates why the model exists: it helps clinicians identify patients who are deteriorating fast and may need aggressive intervention like transplant evaluation.
The ILD-GAP system has also been adapted for specific clinical scenarios. Researchers have modified it into an ILD-NSCLC-GAP index for patients who have both ILD and non-small cell lung cancer, recognizing that having both conditions changes the prognosis dramatically.3PubMed. ILD-NSCLC-GAP index scoring and staging system for patients with non-small cell lung cancer and interstitial lung disease
How Fibrotic ILD Generally Progresses
Even without a formal four-stage system, there is a recognizable arc to how most fibrotic interstitial lung diseases unfold. Thinking of it in broad phases can help patients and families understand what is happening, even if no clinician would stamp a “Stage 2” on a chart.
The process typically begins with repeated small injuries to the delicate lining of the air sacs. Environmental exposures, autoimmune attacks, or unknown triggers damage the alveolar walls, setting off an inflammatory response.4PubMed. Origins of pathological myofibroblasts in lung fibrosis: insights from lineage tracing mouse models in the single-cell RNA sequencing era In some people this inflammation resolves on its own or responds to treatment. In others, the repair process goes haywire. Instead of healing normally, the lungs produce excessive scar tissue.
The cells driving this scarring are called myofibroblasts, and they deposit large amounts of extracellular matrix, a kind of structural scaffolding that stiffens the lung tissue. Growth signals, particularly one called TGF-β1, push these cells to keep producing scar tissue even after the original injury has passed.5PubMed Central. Matrix abnormalities in pulmonary fibrosis As fibrosis accumulates, the lungs become progressively stiffer and less able to exchange oxygen. This is where patients begin to notice that activities they once handled easily now leave them breathless.
In later phases, the scarring becomes extensive enough to cause visible architectural distortion on imaging, including honeycombing (clusters of small cystic spaces where functional lung tissue used to be) and traction bronchiectasis (airways stretched open by the pull of surrounding scar tissue). These features carry real prognostic weight: for every 10% increase in honeycombing visible on CT, the risk of death or needing a transplant rises by about 20%, and a similar increase in traction bronchiectasis raises that risk by roughly 18%.6PubMed. CT Honeycombing and Traction Bronchiectasis Extent Independently Predict Survival across Fibrotic Interstitial Lung Disease Subtypes
Tracking Decline With Lung Function Tests
Because ILD does not have clean stage cutoffs for most subtypes, clinicians rely heavily on lung function testing to track progression. The two numbers that matter most are FVC and DLCO. FVC measures the total volume of air you can forcefully exhale; DLCO measures how efficiently gas transfers across the lung membrane. Both tend to drop as fibrosis worsens, and the rate of decline is often more telling than any single measurement.
A drop in FVC of 5 to 10 percent over six to twelve months is generally considered clinically significant and often prompts treatment changes. DLCO decline tends to track alongside FVC but sometimes picks up gas exchange problems before FVC starts falling, since scarring can impair oxygen transfer without yet shrinking total lung volume.
These numbers also help measure whether treatment is working. In a real-world study comparing patients on antifibrotic drugs to those not receiving them, FVC declined by about 13% over three years in the treated group versus 25% in the untreated group. The difference in DLCO was even more dramatic: a 10% decline with treatment compared to a 26% decline without it.7Archives of Medical Science. Efficacy of Antifibrotics in Slowing FVC and DLCO Decline in Progressive Pulmonary Fibrosis: A Real World Experience Those numbers show that antifibrotics can slow the disease substantially, even if they do not reverse existing damage.
Lower baseline lung function also predicts steeper declines in quality of life. Research shows that patients who start with a lower FVC tend to experience worse psychological well-being over time, while those with lower DLCO report worsening breathlessness and chest symptoms that increasingly limit daily activities.8PubMed Central. Determinants of health-related quality of life decline in interstitial lung disease
Imaging Scores That Help Predict Outcomes
Researchers have been working to combine imaging findings with blood tests to create composite scores that predict who will progress fastest. One such tool is the HTM score, which stands for honeycombing, traction bronchiectasis, and monocytes. Patients score points for how many lung fields show honeycombing or traction bronchiectasis on CT, and whether their blood monocyte count exceeds a certain threshold.9PubMed Central. Clinical, imaging, and blood biomarkers to assess 1-year progression risk in fibrotic interstitial lung diseases-Development and validation of the honeycombing, traction bronchiectasis, and monocyte (HTM)-score Higher scores predict faster progression over the following year. Tools like this are still being refined, but they represent a shift toward staging disease severity by combining multiple data streams rather than relying on any single test.
A blood marker called KL-6 is also gaining attention. Produced by damaged lung cells, KL-6 levels tend to be substantially higher in people with established ILD than in those with early, incidental lung abnormalities found on CT. Using a threshold of 410 units per milliliter, one study found a sensitivity of about 81% for distinguishing true ILD from milder lung abnormalities.10PubMed Central. Krebs von den Lungen-6 as a biomarker for distinguishing between interstitial lung disease and interstitial lung abnormalities based on computed tomography findings While KL-6 is not yet part of a formal staging system, it could eventually help identify people transitioning from early abnormalities into clinically meaningful disease.
Complications That Signal Advanced Disease
One of the clearest markers that ILD has moved into its later phases is the development of pulmonary hypertension, meaning high blood pressure in the arteries of the lungs. As scar tissue replaces healthy lung, the blood vessels that weave through it are damaged or destroyed. The heart’s right side has to pump harder to push blood through the remaining vessels, and eventually that strain takes a toll.
The combination of ILD and pulmonary hypertension is far worse than either condition alone. Some estimates suggest that patients with both have more than three times the mortality of patients with pulmonary arterial hypertension without ILD.11CHEST. Pulmonary Hypertension Associated With Interstitial Lung Diseases Early symptoms of this complication, like worsening breathlessness and fatigue, are easy to attribute to the underlying ILD and can be missed. Advanced cases bring more recognizable signs: leg swelling, abdominal bloating, loss of appetite, and profound fatigue as the right side of the heart fails.12Mayo Clinic Proceedings. Pulmonary Hypertension in Interstitial Lung Disease
Acute exacerbations are another feared complication. These are sudden, severe flare-ups where breathing deteriorates rapidly over days to weeks, often landing patients in the hospital. On imaging they appear as widespread ground-glass opacification, a hazy whitening that indicates fresh damage layered on top of existing scarring. Triggers include respiratory infections, aspiration of stomach contents, and mechanical stress, though in many cases no clear trigger is found.13PubMed Central. Acute Exacerbation in Interstitial Lung Disease Acute exacerbations carry high mortality and can permanently ratchet down lung function in survivors.
Treatment Approaches Across the Disease Course
How ILD is treated depends heavily on its subtype and where a patient falls on the severity spectrum. For ILDs driven by autoimmune or inflammatory processes, immunosuppressive medications are the backbone of treatment. In systemic sclerosis-associated ILD, for instance, mycophenolate and cyclophosphamide have both been shown to slow FVC decline, with rituximab showing promise as well: one trial found a significantly higher proportion of patients experienced lung function improvement with rituximab compared to cyclophosphamide.14Mayo Clinic Proceedings. Management of Connective Tissue Disease–Associated Interstitial Lung Disease: A Review of Clinical Studies
For progressive fibrotic diseases like IPF, the two approved antifibrotic drugs are pirfenidone and nintedanib. Both slow the rate at which lungs scar, though neither stops or reverses the process. Side effects are a genuine barrier: in one hospital registry, nearly half of patients on nintedanib discontinued treatment due to side effects, compared to about 18% on pirfenidone.15PubMed. Pirfenidone and nintedanib in fibrosing interstitial lung disease: A retrospective study based on a regional university hospital data registry and literature review Still, about two-thirds of patients with IPF were continuing their antifibrotic therapy at the one-year mark in that same study, suggesting the benefits are often judged worth the discomfort.
Pulmonary rehabilitation plays a different but important role. Structured exercise and breathing retraining programs improve endurance, reduce breathlessness during daily activities, and boost quality of life. These benefits hold across ILD subtypes, though patients who already need supplemental oxygen at rest tend to gain less from rehabilitation programs.16PubMed. Pulmonary rehabilitation in patients with interstitial lung diseases: Correlates of success Physical activity and walking capacity are closely linked to quality of life in ILD patients, reinforcing that staying as active as possible has direct payoffs for well-being.17Respiratory Physiology & Neurobiology. Impact of physical functional capacity on quality of life in patients with interstitial lung diseases
When Transplant Enters the Picture
Lung transplantation is the only option that can dramatically extend life in advanced fibrotic ILD, and interstitial lung diseases are now the most common reason people receive lung transplants worldwide.18PubMed Central. Lung transplantation for interstitial lung disease Despite that, many eligible patients are either not referred or referred too late. The disease can accelerate unpredictably, and a patient who seemed stable months ago may suddenly find themselves too sick for surgery.
Outcomes after transplant vary considerably. Age matters: recipients over 50 have substantially worse survival compared with younger patients. Bilateral transplants (replacing both lungs) appear to offer a survival advantage in patients under 50, but that benefit disappears in older recipients.19BMJ. Lung transplantation for interstitial lung disease: evolution over three decades The underlying cause of ILD also matters. Patients transplanted for myositis-related ILD, for example, face considerably higher risks of death, blood clots, and infection in the years following transplant compared to those transplanted for IPF.20Journal of Heart and Lung Transplantation Open. Lung Transplantation for Connective Tissue Disease-Related Interstitial Lung Disease: Insights from a Single-Center Cohort
The Illness Journey and Palliative Care
Separate from clinical staging, researchers have identified a three-phase emotional and practical journey that people with progressive fibrotic ILD tend to experience. The first phase involves information seeking: patients are trying to understand what the diagnosis means and what lies ahead. The second is grief and adjustment, as the reality of a life-limiting illness sinks in and daily routines shift to accommodate worsening symptoms. The third is fear of the future, when uncertainty about how fast things will progress becomes the dominant psychological burden.21PubMed Central. When should palliative care be introduced for people with progressive fibrotic interstitial lung disease? A meta-ethnography of the experiences of people with end-stage interstitial lung disease and their family carers
Palliative care is increasingly recognized as something that should be introduced earlier than it traditionally has been, ideally during the grief-and-adjustment phase rather than only at the end of life. This is not about giving up on treatment. Palliative care runs alongside active treatment and focuses on managing symptoms like breathlessness and cough, providing psychological support, and helping families plan for what may come. European Respiratory Society guidelines recommend offering palliative care that includes support for informal caregivers, noting that such interventions reduce anxiety in patients and decrease depression and caregiver burden.22European Respiratory Journal. European Respiratory Society clinical practice guideline: palliative care for people with COPD or interstitial lung disease Triggers for introducing palliative care include new symptoms, respiratory infections, hospital admissions, declining physical function, and the start of supplemental oxygen, all signals that the disease is entering a phase where symptom management and quality of life deserve equal attention alongside efforts to slow the scarring itself.
The Histopathology Problem
One reason staging ILD is so tricky is that different diseases can look identical under the microscope. The most common scarring pattern seen in lung biopsies is called usual interstitial pneumonia (UIP), characterized by patchy, uneven fibrosis where areas of dense scarring sit next to relatively normal tissue. UIP is the expected pattern in IPF, but it can also show up in connective tissue disease-related ILD and chronic hypersensitivity pneumonitis.23PubMed Central. Usual interstitial pneumonia-pattern fibrosis in surgical lung biopsies. Clinical, radiological and histopathological clues to aetiology Because the same tissue pattern can arise from fundamentally different causes, biopsy findings alone cannot tell a clinician which disease they are dealing with, let alone assign a stage. Diagnosis and staging require pulling together imaging, lung function, blood work, clinical history, and sometimes biopsy results in a multidisciplinary team discussion. There is no single test that pins down both what type of ILD a patient has and how advanced it is.
This complexity is worth keeping in mind the next time you encounter a neat four-stage chart online. The reality of ILD classification is that clinicians are juggling multiple overlapping systems, each designed for a different question: what kind of ILD is this, how severe is it right now, how fast is it likely to progress, and what treatment approach fits best. As biomarkers like KL-6 mature and composite scores like the HTM model are validated in larger populations, the hope is that staging will eventually become more standardized. For now, the most useful “stage” for any individual patient is not a number on a chart but a composite picture assembled from their specific imaging findings, lung function trajectory, symptoms, and overall health.